Abstract
Somatostatin was discovered four decades ago and since then its physiological role has been extensively investigated, first in relation with its inhibitory effect on growth hormone secretion but soon it expanded to extrapituitary actions influencing various stressresponsive systems. Somatostatin is expressed in distinct brain nuclei and binds to five somatostatin receptor subtypes which are also widely expressed in the brain with a distinct distribution pattern. The last few years witnessed the discovery of highly selective peptide somatostatin receptor agonists and antagonists representing valuable tools to delineate the respective pathways of somatostatin signaling. Here we review the centrally mediated actions of somatostatin and related selective somatostatin receptor subtype agonists to influence the endocrine, autonomic, and visceral components of the stress response and basal behavior as well as thermogenesis.
Keywords: Autonomic nervous system, fecal pellet output, food intake, gastrointestinal motility, octreotide, ODT8-SST, thermogenesis, somatostatin, growth hormone, stress response
Current Pharmaceutical Design
Title:Central Actions of Somatostatin-28 and Oligosomatostatin Agonists to Prevent Components of the Endocrine, Autonomic and Visceral Responses to Stress Through Interaction with Different Somatostatin Receptor Subtypes
Volume: 19 Issue: 1
Author(s): Andreas Stengel, Jean Rivier and Yvette Tache
Affiliation:
Keywords: Autonomic nervous system, fecal pellet output, food intake, gastrointestinal motility, octreotide, ODT8-SST, thermogenesis, somatostatin, growth hormone, stress response
Abstract: Somatostatin was discovered four decades ago and since then its physiological role has been extensively investigated, first in relation with its inhibitory effect on growth hormone secretion but soon it expanded to extrapituitary actions influencing various stressresponsive systems. Somatostatin is expressed in distinct brain nuclei and binds to five somatostatin receptor subtypes which are also widely expressed in the brain with a distinct distribution pattern. The last few years witnessed the discovery of highly selective peptide somatostatin receptor agonists and antagonists representing valuable tools to delineate the respective pathways of somatostatin signaling. Here we review the centrally mediated actions of somatostatin and related selective somatostatin receptor subtype agonists to influence the endocrine, autonomic, and visceral components of the stress response and basal behavior as well as thermogenesis.
Export Options
About this article
Cite this article as:
Stengel Andreas, Rivier Jean and Tache Yvette, Central Actions of Somatostatin-28 and Oligosomatostatin Agonists to Prevent Components of the Endocrine, Autonomic and Visceral Responses to Stress Through Interaction with Different Somatostatin Receptor Subtypes, Current Pharmaceutical Design 2013; 19 (1) . https://dx.doi.org/10.2174/1381612811306010098
DOI https://dx.doi.org/10.2174/1381612811306010098 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Sympathetic Nerve Activity in Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Role of Brain NUCB2/nesfatin-1 in the Regulation of Food Intake
Current Pharmaceutical Design TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Molecular Pharmacology of Non-L-type Calcium Channels
Current Pharmaceutical Design Aspartame: Should Individuals with Type II Diabetes be Taking it?
Current Diabetes Reviews Gestational Exposure to Variable Stressors Produces Decrements in Cognitive and Neural Development of Juvenile Male and Female Rats
Current Topics in Medicinal Chemistry Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Modulators of Pain: Bv8 and Prokineticins
Current Neuropharmacology Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Therapeutic Approach of Histamine H3 Receptors in Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Carbon Monoxide - Toxicity of Low-Dose Application
Current Pharmaceutical Biotechnology The New Adipose Tissue and Adipocytokines
Current Diabetes Reviews Antidepressants and Sleep: Neurophysiology and Clinical Correlates
Current Psychiatry Reviews Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
Current Drug Targets Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Proteasome Modulator 9 and Depression in Type 2 Diabetes
Current Medicinal Chemistry Sex Differences in Clinical Outcomes of Patients with Stable Coronary Artery Disease after Percutaneous Coronary Intervention
Current Pharmaceutical Design An Overview on Cardiovascular Protective Effects of Catechins
Cardiovascular & Hematological Disorders-Drug Targets